SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Frequently asked questions
What sector does Sophia Genetics SA (SOPH) operate in?
Sophia Genetics SA belongs to the Healthcare sector and operates in the Health Information Services industry.
What is Sophia Genetics SA (SOPH) current stock price?
As of the latest data, Sophia Genetics SA stock price is $7.52, with a previous close of $7.35. Sophia Genetics SA gained $0.17 in the last trading session, representing a 2.31% increase.
What is Sophia Genetics SA (SOPH) current market capitalization?
Sophia Genetics SA market cap is approximately 640.16 million.
What is Sophia Genetics SA (SOPH) Earnings Per Share (EPS)?
The trailing EPS is -$1.16, and the forward EPS is -$0.50.
What is Sophia Genetics SA (SOPH) EBITDA?
Sophia Genetics SA EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -17.75 million.
Does Sophia Genetics SA (SOPH) pay dividends?
No. Sophia Genetics SA does not pay a dividend.
How did Sophia Genetics SA (SOPH) perform in its most recent earnings report?
In the last report (June 30, 2026), Sophia Genetics SA posted an EPS surprise of -73.33% and a revenue surprise of 7.36%.
When is Sophia Genetics SA (SOPH) next earnings report?
Sophia Genetics SA is expected to release its next earnings report on September 30, 2026.
What is Sophia Genetics SA (SOPH) beta (volatility) score?
Sophia Genetics SA has a beta of 0.952, meaning its volatility is roughly in line with the market.
